Captor Therapeutics S.A. (CTX) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.346x

Based on the latest financial reports, Captor Therapeutics S.A. (CTX) has a cash flow conversion efficiency ratio of -0.346x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł-11.51 Million ≈ $-3.17 Million USD) by net assets (zł33.27 Million ≈ $9.16 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Captor Therapeutics S.A. (CTX) total market value for the company's overall valuation and market capitalisation.

Captor Therapeutics S.A. - Cash Flow Conversion Efficiency Trend (2017–2024)

This chart illustrates how Captor Therapeutics S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.

Captor Therapeutics S.A. Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Captor Therapeutics S.A. ranked by their cash flow conversion efficiency. See debt repayment capacity of Captor Therapeutics S.A. to evaluate how effectively operating cash flow covers total debt obligations.

Company	Cash Flow Conversion Efficiency
AURRIGO INT.PLCLS-002 F:CI0	N/A
Jindal Poly Investment and Finance Company Limited NSE:JPOLYINVST	0.004x
Lassila &Tikanoja Oyj HE:LAT1V	0.070x
Samwha Electri KO:009470	0.025x
Amulaire Thermal Technology TW:2241	0.007x
Kyung Nong Corporation KO:002100	-0.087x
Sat Industries Limited NSE:SATINDLTD	0.006x
China Reform Culture Holdings Co Ltd SHG:600636	0.005x

Annual Cash Flow Conversion Efficiency for Captor Therapeutics S.A. (2017–2024)

The table below shows the annual cash flow conversion efficiency of Captor Therapeutics S.A. from 2017 to 2024. View Captor Therapeutics S.A. (CTX) share price today for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	zł64.47 Million ≈ $17.74 Million	zł-31.88 Million ≈ $-8.77 Million	-0.494x	+34.44%
2023-12-31	zł69.22 Million ≈ $19.05 Million	zł-52.20 Million ≈ $-14.37 Million	-0.754x	-216.56%
2022-12-31	zł96.32 Million ≈ $26.51 Million	zł-22.95 Million ≈ $-6.32 Million	-0.238x	-3.92%
2021-12-31	zł124.20 Million ≈ $34.18 Million	zł-28.47 Million ≈ $-7.84 Million	-0.229x	-138.68%
2020-12-31	zł-1.00 Million ≈ $-276.32K	zł-595.00K ≈ $-163.75K	0.593x	-42.31%
2019-12-31	zł4.28 Million ≈ $1.18 Million	zł4.39 Million ≈ $1.21 Million	1.027x	+265.41%
2018-12-31	zł3.43 Million ≈ $944.26K	zł-2.13 Million ≈ $-586.48K	-0.621x	-104.27%
2017-12-31	zł144.00K ≈ $39.63K	zł2.10 Million ≈ $577.12K	14.563x	--

About Captor Therapeutics S.A.

WAR:CTX Poland Biotechnology

Market Cap

$109.92 Million

zł399.38 Million PLN

Market Cap Rank

#18925 Global

#144 in Poland

Share Price

zł72.50

Change (1 day)

+0.28%

52-Week Range

zł35.50 - zł87.60

All Time High

zł202.00